Crystal Habit Modification to Improve Powder Flowability, a Case Study

Monday, November 8, 2010: 4:55 PM
Grand Ballroom D (Salt Palace Convention Center)
Lotfi Derdour1, Dimitri Skliar2, Daniel Hallow2, Jun Li2, Michael Randazzo2 and Frederic Buono2, (1)Process Research and Development, Bristol-Myers Squibb Co, New Brunswick, NJ, (2)P R&D, Bristol-Myers Squibb Co, New Brunswick, NJ

In this investigation, experimental studies and possible mechanisms leading to the crystal habit modification of a developmental drug will be discussed. Crystallization was performed in various ways including anti-solvent addition and cooling crystallization. However, in all cases, the drug particles crystallized as long needles that resulted in poor powder flowability which was not suitable for formulation. Crystal engineering efforts were undertaken to improve the powder flowability by decreasing the aspect ratio of the primary drug particles. From the crystal habit modification techniques attempted, it was found that a combination of temperature cycling, “in situ seed generation” and wet milling was the technique that provided the largest decrease in the aspect ratio of primary drug particles. This resulted in a significant improvement of the powder flowability which enabled the formulation of the drug product.

Extended Abstract: File Not Uploaded
See more of this Session: Integrated API and Drug Product Development
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division